NIOX GROUP
PLC
("NIOX"
or the "Company"
and, together with its subsidiaries, the
"Group")
Directorate
Change
Oxford, UK - 1 July 2024: NIOX
Group plc (AIM: NIOX), a medical device company focused on point of
care asthma diagnosis and management, is pleased to announce the
appointment of Robert Naylor as Non-Executive Director and Chair of
the Audit and Risk Committee, with immediate effect.
Robert has over 25 years' experience
in capital markets specialising in healthcare and investment
companies and is currently Chief Executive Officer of Intuitive
Investments Group plc, an investment company which is quoted on the
Specialist Fund Segment of the London Stock Exchange's Main Market,
providing investors with exposure to a portfolio of fast-growing
technology and life sciences businesses. Additionally, Robert is
Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250
company, which is currently subject to a recommended cash offer by
Lyra Bidco Limited, a newly-formed company indirectly wholly-owned
by investment funds advised by affiliates of Blackstone
Inc.
Previously, Robert was Non-Executive
Chairman of Round Hill Music Royalty Fund Limited and oversaw its
sale to a company directly owned by Alchemy Copyrights, LLC,
trading as Concord. He has also served as a Non-Executive Director
of Light Science Technologies Holdings plc, an AIM-quoted
controlled environment agriculture company. Earlier in his career
Robert held various positions within JP Morgan Asset Management
Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc.
Robert is a qualified chartered accountant, having started his
career with Ernst & Young in 1996.
Ian Johnson, NIOX's Executive
Chairman, said: "I am delighted to welcome
Robert to the NIOX Board and look forward to working with him as we
continue to build on our global leadership. Robert brings extensive
business and corporate development experience to assist the
executive team in implementing its growth
strategy."
Additional information in respect of the AIM
Rules
The following information regarding
the appointment of Robert Graham Naylor (aged 49) is disclosed
pursuant to Schedule Two paragraph (g) of the AIM Rules for
Companies ("AIM Rules"):
|
Current directorships/partnerships
|
Past
directorships/partnerships
|
|
· Intuitive Investments Group Plc
· IIG
Assets Ltd
· Hipgnosis SFH XX Limited
· Hipgnosis SFH XIII Limited
· Hipgnosis SFH XIX Limited
· Hipgnosis SFH I Limited
· Hipgnosis Holdings UK Limited
· Rubyruby (London) Limited
· Pb
Songs Ltd
· Kennedy Publishing & Productions Limited
· Deamon
Limited
|
· Round
Hill Music Royalty Fund Limited
· RHMRF2
Limited
· RHMRF3
Limited
· Light
Science Technologies Holdings plc
· Concord Copyrights No.1 Limited (formerly RHMRF1
Limited)
|
As at the date of this announcement,
Robert Naylor holds no interest in the Company.
Save as set out above, there is no
further information to be disclosed in respect of Robert Naylor
under Schedule 2(g) of the AIM Rules for Companies.
|
Contacts:
|
|
NIOX Group
plc
Ian Johnson,
Executive Chairman
Michael Roller, Chief Financial
Officer
|
+44 (0) 3303 309 356
|
|
Singer Capital Markets
(Nominated Adviser and Joint Broker)
Aubrey Powell / Jen Boorer / James
Todd
|
+44 (0) 20 7496 3000
|
|
Investec Bank plc (Financial
Adviser and Joint Broker)
Edward Knight / Bruce Garrow / Lydia
Zychowska
|
+44 (0) 20 7597 4000
|
About NIOX
Our mission is to improve asthma
diagnosis and management by greater patient access to FeNO testing.
Asthma is one of the biggest healthcare issues globally with 340
million sufferers, many of whom are undiagnosed or are
misdiagnosed. The Group is engaged in the design, development, and
commercialisation of medical devices for the measurement of FeNO, a
precise biomarker for asthma. Our market leading device, NIOX
VERO®, is increasingly recognised by
healthcare professionals as an important tool to improve the
diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical
research organisations for respiratory studies.
NIOX provides products and services
via its direct sales organisation and extensive distributor network
in 50 countries. For more information, please visit
www.niox.com
